Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis

NIH RePORTER · NIH · R01 · $473,302 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY THE ROLE OF FBXO45 IN DIFFUSE LARGE B-CELL LYMPHOMA PATHOGENESIS Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma and represents the most common form of malignant lymphoma in the western hemisphere. The biologic events underlying the pathogenesis of DLBCL are not completely understood. We have recently identified functional inactivation of FBXO45, an E3 ubiquitin ligase in DLBCL. In this application, we will utilize transgenic mouse models to explore the biological roles for FBXO45 in B-cell differentiation and lymphomagenesis. Further, we will employ biochemical and molecular biology techniques to better understand the role FBXO45 in the pathogenesis of DLBCL. Accordingly, we propose in the first aim of this application to utilize newly created transgenic mouse models to functionally interrogate the role of FBXO45 in B- cell development and lymphomagenesis. In the second aim, we will identify the global cellular substrates of FBXO45 in B cell contexts. These studies will establish the role of FBXO45 in the pathogenesis of DLBCL and establish the mechanisms by which its deregulation contributes to DLBCL.

Key facts

NIH application ID
10240270
Project number
5R01CA231021-03
Recipient
UNIVERSITY OF PENNSYLVANIA
Principal Investigator
KOJO S. J. ELENITOBA-JOHNSON
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$473,302
Award type
5
Project period
2019-07-03 → 2024-06-30